UBS Group
MRNS

UBS Group’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

UBS Group’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-258,944
Closed -$139K – 11063
2024
Q4 		$139K Buy
258,944
+256,686
+11,368% +$179K ﹤0.01% 6678
2024
Q3 		$3.97K Sell
2,258
-16,787
-88% -$23.4K ﹤0.01% 8198
2024
Q2 		$22.3K Sell
19,045
-104,807
-85% -$262K ﹤0.01% 7237
2024
Q1 		$1.12M Buy
123,852
+40,782
+49% +$396K ﹤0.01% 4512
2023
Q4 		$903K Buy
83,070
+26,926
+48% +$202K ﹤0.01% 4594
2023
Q3 		$452K Buy
56,144
+20,171
+56% +$168K ﹤0.01% 4735
2023
Q2 		$391K Sell
35,973
-48,779
-58% -$418K ﹤0.01% 5027
2023
Q1 		$585K Buy
84,752
+8,916
+12% +$55.9K ﹤0.01% 4568
2022
Q4 		$302K Sell
75,836
-20,539
-21% -$101K ﹤0.01% 5124
2022
Q3 		$641K Buy
96,375
+178
+0.2% +$1.1K ﹤0.01% 4126
2022
Q2 		$465K Buy
96,197
+62,260
+183% +$379K ﹤0.01% 4313
2022
Q1 		$317K Sell
33,937
-16,277
-32% -$162K ﹤0.01% 5023
2021
Q4 		$597K Buy
50,214
+18,096
+56% +$209K ﹤0.01% 4829
2021
Q3 		$366K Buy
32,118
+1,467
+5% +$20.2K ﹤0.01% 4921
2021
Q2 		$550K Buy
30,651
+9,642
+46% +$155K ﹤0.01% 4651
2021
Q1 		$325K Buy
21,009
+412
+2% +$5.96K ﹤0.01% 5167
2020
Q4 		$252K Buy
20,597
+6,455
+46% +$90K ﹤0.01% 5095
2020
Q3 		$182K Sell
14,142
-35
-0.2% -$302 ﹤0.01% 4843
2020
Q2 		$144K Sell
14,177
-2,947
-17% -$27.1K ﹤0.01% 5040
2020
Q1 		$139K Sell
17,124
-4,898
-22% -$42.4K ﹤0.01% 5014
2019
Q4 		$191K Buy
22,022
+5,365
+32% +$30.1K ﹤0.01% 5632
2019
Q3 		$103K Sell
16,657
-2,526
-13% -$20.4K ﹤0.01% 5751
2019
Q2 		$318K Buy
19,183
+969
+5% +$16.8K ﹤0.01% 4615
2019
Q1 		$305K Sell
18,214
-3,202
-15% -$46.1K ﹤0.01% 4361
2018
Q4 		$246K Buy
21,416
+87
+0.4% +$1.76K ﹤0.01% 4803
2018
Q3 		$853K Buy
21,329
+1,760
+9% +$50.1K ﹤0.01% 3995
2018
Q2 		$553K Buy
+19,569
New +$434K ﹤0.01% 4244
2018
Q1 		– Sell
-3
Closed – – 8250
2017
Q4 		$0 Buy
+3
New +$81 ﹤0.01% 8168
2017
Q3 		– Sell
-654
Closed -$4K – 8077
2017
Q2 		$4K Sell
654
-2,019
-76% -$10.9K ﹤0.01% 7231
2017
Q1 		$19K Sell
2,673
-2,233
-46% -$12K ﹤0.01% 6182
2016
Q4 		$20K Sell
4,906
-1,075
-18% -$5K ﹤0.01% 6526
2016
Q3 		$44K Buy
5,981
+1,168
+24% +$7.9K ﹤0.01% 5621
2016
Q2 		$24K Sell
4,813
-462
-9% -$8.51K ﹤0.01% 6158
2016
Q1 		$113K Buy
5,275
+3,985
+309% +$84.4K ﹤0.01% 4886
2015
Q4 		$39K Buy
1,290
+1,128
+696% +$33.1K ﹤0.01% 6064
2015
Q3 		$5K Sell
162
-19
-10% -$1.07K ﹤0.01% 7738
2015
Q2 		$8K Buy
+181
New +$6.76K ﹤0.01% 7629

UBS Group's MRNS Position: Q1 2025 in Review

UBS Group sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 258,944 shares — an estimated $139K sold.

UBS Group first reported a position in MRNS in Q2 2015 and held it in 37 quarters. The position peaked at $1.12M in Q1 2024. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.

  • UBS Group reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
  • UBS Group sold 258,944 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $139K.
  • UBS Group first reported a position in Marinus Pharmaceuticals, Inc in Q2 2015 and held it in 37 quarters.
  • UBS Group's Marinus Pharmaceuticals, Inc position peaked at $1.12M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.